Abstract
Background
Vaccination against SARS-COV-2 has been the most important strategy for preventing infection of Coronavirus disease 2019 (COVID-19). Breast cancer is the most common malignancy in women, but there is a lack of research on the pandemics in postoperative patients with breast cancer.
Objective
To investigate the rate and factors for SARS-CoV-2 vaccination and adverse reactions after vaccination in postoperative patients with breast cancer.
Methods
A web-based questionnaire survey on SARS-CoV-2 vaccination in postoperative patients with breast cancer among women.
Results
A total of 947 online questionnaires were collected. Of these, 341 accepted SARS-CoV-2 vaccination, while 606 were not vaccinated. There were significant differences in age, current treatment, the time since surgery, and the symptoms of anxiety and depression between the two groups. We identified current treatment (OR=0.51 for endocrine therapy; 95% CI: 0.29-0.89), the time since surgery (OR=22.49 for 1-2 years; 95% CI: 12.31-41.10; OR=8.49 for 2-5 years ; 95% CI: 4.98-14.46; OR=1.79 for >5 years ; 95% CI: 1.11-2.89), and the symptoms of depression (OR=2.48; 95% CI: 1.19-5.15) as significant factors for unvaccination. The overall incidence of adverse reactions was 43.1%. The most common local and systemic adverse reactions were pain at the injection site (28.4%) and fatigue (8.8%), respectively.
Conclusion
Postoperative patients with breast cancer have a relatively lower rate of vaccination for SARS-CoV-2 than the general population. Receiving treatment, a shorter time since surgery and symptom of depression were associated with unvaccination. More importantly, a favorable safety profile of the vaccines is indicated.